Nuclear Receptor DNA Binding in Human Physiology and Disease
人类生理和疾病中的核受体 DNA 结合
基本信息
- 批准号:8438380
- 负责人:
- 金额:$ 36.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-03-05 至 2016-02-29
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdverse effectsAffectAffinityAlcohol consumptionBindingBinding SitesBiochemicalBioinformaticsBiological AssayBody WeightCodeCustomDNADNA BindingDNA SequenceDataData SetDatabasesDiabetes MellitusDiseaseDisease susceptibilityDrug TargetingEnsureEye ColorFoundationsGene ExpressionGene TargetingGenesGeneticGenetic PolymorphismGenomeGenomicsGenotypeGoalsHair ColorHealth Care CostsHeart DiseasesHormonesHumanImmunofluorescence ImmunologicIn VitroIndividualLeadLearningLifeLigandsLinkLocationMalignant NeoplasmsMammalian CellMedicineMental disordersMolecularMonozygotic twinsMuscle TonusMutationNuclear ReceptorsNucleic Acid Regulatory SequencesNucleotidesOnline SystemsPharmaceutical PreparationsPhysiologicalPhysiologyPlayPredispositionProtein BindingProteinsQuantitative Trait LociReactionResearchResponse ElementsRoleSingle Nucleotide PolymorphismSpecificitySpottingsTechnologyTissuesUnited States National Institutes of HealthVariantVitaminsbasedesigndrug metabolismgenetic associationgenome wide association studygenome-widekinetosomenew technologynovelpreferenceprotein functionreceptor bindingresearch studyresponsetooltranscription factorweb site
项目摘要
DESCRIPTION (provided by applicant): Nuclear receptors (NRs) are ligand-dependent transcription factors that regulate the expression of a wide variety of genes involved in nearly al aspects of human physiology and disease. They do so in large part by first binding specific DNA response elements (RE) in regulatory regions of genes. While the past 25+ years has led to a basic understanding of NR DNA binding, recent studies indicate that we have much more to learn about the NR-DNA interaction, and the factors that influence it. Furthermore, while NRs have been investigated heavily for their role in physiology and disease and are themselves targets of many successful drugs, we still do not have a complete understanding of their role in disease susceptibility nor in individual responses to drug treatments. Variability between individuals is determined at least partially by their genetic make-up and single nucleotide polymorphisms (SNPs) are thought to account for much that variability. While many SNPs in the coding portion of genes have been associated with altered protein function, recent genome-wide studies show that certain SNPs are associated with changes in levels of expression of nearby genes (eSNPs). However, what is lacking is a systematic, functional characterization of eSNPs. We propose that a significant proportion SNPs affect gene expression by altering the affinity of NRs for their DNA response elements. In this proposal, we will examine NR DNA binding specificity and how it is influenced by SNPs by integrating a range of biochemical, molecular, genomic and bioinformatics approaches in three Specific Aims: In Aim 1, we will exhaustively determine the DNA binding specificity of a select group of NRs using an integrated approach based on protein binding microarrays (PBMs). PBMs are a novel, high throughput (10- 100,000's reactions) in vitro DNA binding assay. The PBM results will be used to search the genome for potential NR target genes and then cross referenced with genome-wide location and expression analysis. In Aim 2, we will expand PBMs to 1 million reactions in order to identify affinity altering SNPs (aaSNPs) for NRs in regulatory regions of genes associated with disease and drug metabolism. The results from the SNP PBMs will be cross referenced with publicly available databases (GWAS, dbSNP, GTEx, etc.) in order identify aaSNPs that have effects on expression levels of genes relevant to disease and drug metabolism. In Aim 3, PBMs will be used to investigate the effect of a variety of factors on NR DNA binding, including different ligands, NR partners, co-regulatory molecules. All results will be made publically available on a website dedicated to the project, as well as other public databases, and web-based tools for motif finding and target gene prediction will be developed. They will advance the long term goal of fast tracking research linking NRs to disease and drug metabolism, and thereby help personalize medicine and ensure that drugs that target NRs can be used in a more effective fashion.
描述(由申请人提供):核受体(NR)是配体依赖性转录因子,调节涉及人类生理学和疾病的几乎所有方面的多种基因的表达。它们在很大程度上是通过首先结合基因调控区域中的特定 DNA 反应元件 (RE) 来实现这一点的。虽然过去 25 年多的时间人们对 NR DNA 结合有了基本的了解,但最近的研究表明,我们对 NR-DNA 相互作用以及影响它的因素还有更多需要了解。此外,虽然 NR 在生理学和疾病中的作用已被广泛研究,并且它们本身也是许多成功药物的靶标,但我们仍然没有完全了解它们在疾病易感性或个体对药物治疗的反应中的作用。个体之间的变异至少部分是由其基因组成决定的,单核苷酸多态性(SNP)被认为是造成这种变异的主要原因。虽然基因编码部分的许多 SNP 与蛋白质功能改变有关,但最近的全基因组研究表明,某些 SNP 与附近基因 (eSNP) 表达水平的变化有关。然而,缺乏的是 eSNP 的系统、功能表征。我们认为,很大一部分 SNP 通过改变 NR 与其 DNA 反应元件的亲和力来影响基因表达。 在本提案中,我们将通过在三个具体目标中整合一系列生化、分子、基因组和生物信息学方法来检查 NR DNA 结合特异性以及它如何受到 SNP 的影响:在目标 1 中,我们将详尽地确定 NR DNA 结合特异性使用基于蛋白质结合微阵列 (PBM) 的集成方法选择 NR 组。 PBM 是一种新型、高通量(10-100,000 次反应)的体外 DNA 结合测定。 PBM 结果将用于在基因组中搜索潜在的 NR 靶基因,然后与全基因组定位和表达分析交叉引用。 在目标 2 中,我们将 PBM 扩展到 100 万个反应,以便识别与疾病和药物代谢相关的基因调控区域中 NR 的亲和力改变 SNP (aaSNP)。 SNP PBM 的结果将与公开数据库(GWAS、dbSNP、GTEx 等)交叉引用,以确定对疾病和药物代谢相关基因的表达水平有影响的 aaSNP。 在目标 3 中,PBM 将用于研究多种因素对 NR DNA 结合的影响,包括不同的配体、NR 伴侣、共调节分子。 所有结果将在该项目专用网站以及其他公共数据库上公开发布,并将开发基于网络的基序发现和目标基因预测工具。他们将推进将 NR 与疾病和药物代谢联系起来的快速追踪研究的长期目标,从而帮助个性化医疗并确保针对 NR 的药物能够以更有效的方式使用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FRANCES M. SLADEK其他文献
FRANCES M. SLADEK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FRANCES M. SLADEK', 18)}}的其他基金
Balance between HNF4a isoforms in the carbohydrate-lipid metabolic switch
碳水化合物-脂质代谢开关中 HNF4a 亚型之间的平衡
- 批准号:
10663333 - 财政年份:2021
- 资助金额:
$ 36.67万 - 项目类别:
Balance between HNF4a isoforms in the carbohydrate-lipid metabolic switch
碳水化合物-脂质代谢开关中 HNF4a 亚型之间的平衡
- 批准号:
10663333 - 财政年份:2021
- 资助金额:
$ 36.67万 - 项目类别:
Balance between HNF4a isoforms in the carbohydrate-lipid metabolic switch
碳水化合物-脂质代谢开关中 HNF4a 亚型之间的平衡
- 批准号:
10367664 - 财政年份:2021
- 资助金额:
$ 36.67万 - 项目类别:
Nuclear Receptor DNA Binding in Human Physiology and Disease
人类生理和疾病中的核受体 DNA 结合
- 批准号:
8258935 - 财政年份:2012
- 资助金额:
$ 36.67万 - 项目类别:
Nuclear Receptor DNA Binding in Human Physiology and Disease
人类生理和疾病中的核受体 DNA 结合
- 批准号:
8819128 - 财政年份:2012
- 资助金额:
$ 36.67万 - 项目类别:
Nuclear Receptor DNA Binding in Human Physiology and Disease
人类生理和疾病中的核受体 DNA 结合
- 批准号:
8619619 - 财政年份:2012
- 资助金额:
$ 36.67万 - 项目类别:
Endogenous HNF4 Ligands in Physiology and Disease
生理学和疾病中的内源性 HNF4 配体
- 批准号:
6959131 - 财政年份:2005
- 资助金额:
$ 36.67万 - 项目类别:
Endogenous HNF4 Ligands in Physiology and Disease
生理学和疾病中的内源性 HNF4 配体
- 批准号:
7140268 - 财政年份:2005
- 资助金额:
$ 36.67万 - 项目类别:
相似国自然基金
基于真实世界医疗大数据的中西药联用严重不良反应监测与评价关键方法研究
- 批准号:82274368
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
OR10G7错义突变激活NLRP3炎症小体致伊马替尼严重皮肤不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于隐狄利克雷分配模型的心血管系统药物不良反应主动监测研究
- 批准号:82273739
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于真实世界数据的创新药品上市后严重罕见不良反应评价关键方法研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
D.formicigenerans菌通过调控FoxP3-Treg影响PD-1抑制剂所致免疫相关不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Multifunctional Nanoparticle Platform to Prevent Alcohol-Associated HCC Development
多功能纳米颗粒平台可预防酒精相关的 HCC 发展
- 批准号:
10736984 - 财政年份:2023
- 资助金额:
$ 36.67万 - 项目类别:
Impact of Structural Racism on Racial Disparities in Cognitive Impairment
结构性种族主义对认知障碍种族差异的影响
- 批准号:
10572864 - 财政年份:2023
- 资助金额:
$ 36.67万 - 项目类别:
Neural and Renal Contributions to Hypertension with Androgen Deprivation Therapy
雄激素剥夺疗法对高血压的神经和肾脏影响
- 批准号:
10662133 - 财政年份:2023
- 资助金额:
$ 36.67万 - 项目类别:
Physical Frailty and Symptom Monitoring and Management Behaviors in Heart Failure (PRISM-HF)
心力衰竭的身体虚弱和症状监测和管理行为 (PRISM-HF)
- 批准号:
10740609 - 财政年份:2023
- 资助金额:
$ 36.67万 - 项目类别:
ELEVATE Center: Reduction of Maternal Morbidity from Substance Use Disorder in Utah
ELEVATE 中心:降低犹他州药物使用障碍导致的孕产妇发病率
- 批准号:
10748243 - 财政年份:2023
- 资助金额:
$ 36.67万 - 项目类别: